Cargando…

Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management

Multiple myeloma is the second-most common hematologic malignancy in adults worldwide. Despite ongoing advancement in therapeutic modalities, it remains an incurable disease with a 5-year survival rate of approximately 50%. The recent development and introduction of anti-BCMA immunotherapies into cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Markouli, Mariam, Ullah, Fauzia, Unlu, Serhan, Omar, Najiullah, Lopetegui-Lia, Nerea, Duco, Marissa, Anwer, Faiz, Raza, Shahzad, Dima, Danai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378049/
https://www.ncbi.nlm.nih.gov/pubmed/37504327
http://dx.doi.org/10.3390/curroncol30070467
_version_ 1785079669560705024
author Markouli, Mariam
Ullah, Fauzia
Unlu, Serhan
Omar, Najiullah
Lopetegui-Lia, Nerea
Duco, Marissa
Anwer, Faiz
Raza, Shahzad
Dima, Danai
author_facet Markouli, Mariam
Ullah, Fauzia
Unlu, Serhan
Omar, Najiullah
Lopetegui-Lia, Nerea
Duco, Marissa
Anwer, Faiz
Raza, Shahzad
Dima, Danai
author_sort Markouli, Mariam
collection PubMed
description Multiple myeloma is the second-most common hematologic malignancy in adults worldwide. Despite ongoing advancement in therapeutic modalities, it remains an incurable disease with a 5-year survival rate of approximately 50%. The recent development and introduction of anti-BCMA immunotherapies into clinical practice, including chimeric antigen receptor T-cell (CAR-T) therapies and bispecific antibodies, has radically shifted the treatment paradigm. However, despite the promising potential of these therapies for broader application, frequent and significant adverse effects have been reported, both in short- and in long-term settings, requiring increasing awareness and vigilance in the treating team, close monitoring, and prompt interventions with a multidisciplinary approach. In this review, we will discuss the toxicities associated with CAR-T cell and bispecific antibody therapies, focusing on results from major clinical studies and real-world observations. In addition, we will emphasize on effective strategies for prevention, monitoring and management, and provide expert recommendations.
format Online
Article
Text
id pubmed-10378049
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103780492023-07-29 Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management Markouli, Mariam Ullah, Fauzia Unlu, Serhan Omar, Najiullah Lopetegui-Lia, Nerea Duco, Marissa Anwer, Faiz Raza, Shahzad Dima, Danai Curr Oncol Review Multiple myeloma is the second-most common hematologic malignancy in adults worldwide. Despite ongoing advancement in therapeutic modalities, it remains an incurable disease with a 5-year survival rate of approximately 50%. The recent development and introduction of anti-BCMA immunotherapies into clinical practice, including chimeric antigen receptor T-cell (CAR-T) therapies and bispecific antibodies, has radically shifted the treatment paradigm. However, despite the promising potential of these therapies for broader application, frequent and significant adverse effects have been reported, both in short- and in long-term settings, requiring increasing awareness and vigilance in the treating team, close monitoring, and prompt interventions with a multidisciplinary approach. In this review, we will discuss the toxicities associated with CAR-T cell and bispecific antibody therapies, focusing on results from major clinical studies and real-world observations. In addition, we will emphasize on effective strategies for prevention, monitoring and management, and provide expert recommendations. MDPI 2023-07-01 /pmc/articles/PMC10378049/ /pubmed/37504327 http://dx.doi.org/10.3390/curroncol30070467 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Markouli, Mariam
Ullah, Fauzia
Unlu, Serhan
Omar, Najiullah
Lopetegui-Lia, Nerea
Duco, Marissa
Anwer, Faiz
Raza, Shahzad
Dima, Danai
Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management
title Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management
title_full Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management
title_fullStr Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management
title_full_unstemmed Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management
title_short Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management
title_sort toxicity profile of chimeric antigen receptor t-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378049/
https://www.ncbi.nlm.nih.gov/pubmed/37504327
http://dx.doi.org/10.3390/curroncol30070467
work_keys_str_mv AT markoulimariam toxicityprofileofchimericantigenreceptortcellandbispecificantibodytherapiesinmultiplemyelomapathogenesispreventionandmanagement
AT ullahfauzia toxicityprofileofchimericantigenreceptortcellandbispecificantibodytherapiesinmultiplemyelomapathogenesispreventionandmanagement
AT unluserhan toxicityprofileofchimericantigenreceptortcellandbispecificantibodytherapiesinmultiplemyelomapathogenesispreventionandmanagement
AT omarnajiullah toxicityprofileofchimericantigenreceptortcellandbispecificantibodytherapiesinmultiplemyelomapathogenesispreventionandmanagement
AT lopeteguilianerea toxicityprofileofchimericantigenreceptortcellandbispecificantibodytherapiesinmultiplemyelomapathogenesispreventionandmanagement
AT ducomarissa toxicityprofileofchimericantigenreceptortcellandbispecificantibodytherapiesinmultiplemyelomapathogenesispreventionandmanagement
AT anwerfaiz toxicityprofileofchimericantigenreceptortcellandbispecificantibodytherapiesinmultiplemyelomapathogenesispreventionandmanagement
AT razashahzad toxicityprofileofchimericantigenreceptortcellandbispecificantibodytherapiesinmultiplemyelomapathogenesispreventionandmanagement
AT dimadanai toxicityprofileofchimericantigenreceptortcellandbispecificantibodytherapiesinmultiplemyelomapathogenesispreventionandmanagement